 | • レポートコード：PMR210120 • 出版社/出版日：Persistence Market Research / 2020年11月11日 • レポート形態：英文、PDF、314ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User（1名用） | ￥695,800 (USD4,900) | ▷ お問い合わせ |
| Site Licence（同一拠点内共有可） | ￥1,079,200 (USD7,600) | ▷ お問い合わせ |
| Enterprise wide（複数拠点内共有可） | ￥1,505,200 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査資料では、世界の自己調整血漿（ACP）治療市場について調査し、エグゼクティブサマリー、市場概要、主要市場動向、市場背景、市場状況、規模分析・予測、価格分析、構成種類別（純粋多血小板血漿（P-PRP）、白血球・多血小板血漿（LPRP）、純粋血小板に富むフィブリン（P-PRF）、白血球・血小板に富むフィブリン（L-PRF））分析、ソース別（自家血小板に富む血漿、同種血小板に富む血漿、同族体血小板に富む血漿）分析、疾患別（皮膚潰瘍、骨折・移植片、プロテーゼ手術、口腔インプラント、スポーツ傷害・外傷）分析、エンドユーザー別（病院、専門クリニック、外来手術センター、整形手術・外傷センター、研究機関）分析、地域別分析、市場構造分析、競争分析、仮定、調査手法などを掲載しています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・市場背景 ・市場状況 ・規模分析・予測 ・価格分析 ・世界の自己調整血漿（ACP）治療市場規模：構成種類別（純粋多血小板血漿（P-PRP）、白血球・多血小板血漿（LPRP）、純粋血小板に富むフィブリン（P-PRF）、白血球・血小板に富むフィブリン（L-PRF）） ・世界の自己調整血漿（ACP）治療市場規模：ソース別（自家血小板に富む血漿、同種血小板に富む血漿、同族体血小板に富む血漿） ・世界の自己調整血漿（ACP）治療市場規模：疾患別（皮膚潰瘍、骨折・移植片、プロテーゼ手術、口腔インプラント、スポーツ傷害・外傷） ・世界の自己調整血漿（ACP）治療市場規模：エンドユーザー別（病院、専門クリニック、外来手術センター、整形手術・外傷センター、研究機関） ・世界の自己調整血漿（ACP）治療市場規模：地域別 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Autologous Conditioned Plasma Therapy Market – Scope of the Report
A latest publication by Persistence Market Research (PMR) on the global autologous conditioned plasma therapy market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global autologous conditioned plasma therapy market. The study offers detailed insights on key market dynamics, which includes the drivers, restraints, trends, and opportunities in the autologous conditioned plasma therapy market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2020-2030.
Important indicators for the successful growth of the autologous conditioned plasma therapy market are presented in this comprehensive report, which include supply chain analysis, value chain analysis, Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR. This research study can support readers to know the demand for autologous conditioned plasma therapy and quantitative development opportunities during the study period.
The research is beneficial for shareholders in the autologous conditioned plasma therapy market, including investors and service providers, and can help them in developing suitable business strategies to flourish in the autologous conditioned plasma therapy market. The insights and wisdom presented in this PMR study can be leveraged by shareholders in the autologous conditioned plasma therapy market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the autologous conditioned plasma therapy market are also included in the current study. Depending on potential developments in the autologous conditioned plasma therapy market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this market report, minor companies and new entrants in the autologous conditioned plasma therapy industry can be aided in making suitable company choices to achieve traction in the market landscape. Key Questions Answered in PMR’s Autologous Conditioned Plasma Therapy Market Report
Which regions will continue to remain most profitable regional market for autologous conditioned plasma therapy market players?
Which factors will induce a change in the demand for autologous conditioned plasma therapy during the assessment period?
How will COVID-19 change the trends of the autologous conditioned plasma therapy market?
How can market players capture the low-hanging opportunities in the autologous conditioned plasma therapy market in developed regions?
What are the winning strategies of stakeholders in the autologous conditioned plasma therapy market to upscale their position in this landscape?
What are the restraints that investors need to be aware of and tackle while investing in the autologous conditioned plasma therapy market?
What are the developmental trends in autologous conditioned plasma therapy sectors that will impact the market?
How can businesses in the autologous conditioned plasma therapy market avail the growth opportunities in developed and emerging economies?
Autologous Conditioned Plasma Therapy Market: Research Methodology
In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the autologous conditioned plasma therapy market, and reach conclusions on future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the autologous conditioned plasma therapy market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts interviewed specialized industry experts, medical professionals with autologous conditioned plasma therapy surgeries, and key executives of product manufacturing companies, who have contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the autologous conditioned plasma therapy market, and makes PMR’s projections on the growth prospects of the autologous conditioned plasma therapy market more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Market Background
4.1. COVID19 Crisis Analysis
4.1.1. Current COVID19 Statistics and Probable Future Impact
4.1.2. Current GDP Projection and Probable Impact
4.1.3. Current Economic Projection as compared to 2008 Economic analysis
4.1.4. COVID19 and Impact Analysis
4.1.4.1. Revenue By Composition Type
4.1.4.2. Revenue By Source
4.1.4.3. Revenue By Country
4.1.5. 2020 Market Scenario
4.1.6. Quarter by Quarter Forecast
4.1.7. Projected recovery Quarter
4.1.8. Recovery Scenario – Short term, Midterm and Long Term Impact
4.2. Macro-Economic Factors
4.2.1. Global GDP Growth Outlook
4.2.2. Global Healthcare Outlook
4.3. Forecast Factors – Relevance & Impact
4.3.1. Historical Growth of Top Players
4.3.2. Technological Advancement
4.3.3. Adoption of Autologous Conditioned Plasma Therapy Therapy
4.3.4. Cost of Autologous Conditioned Plasma Therapy Therapy
4.3.5. Increasing Prevalence of Surgical Conditions
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
5. Market Context
5.1. PRP’s Patient Share Analysis
5.1.1. By Skin Ulcers Sub-indications
5.1.1.1. Venous Ulcers
5.1.1.2. Arterial Ulcers
5.1.1.3. Diabetic Foot Ulcers
5.1.2. By Skin Ulcers Severity Stages
5.1.2.1. Mild Stage (Acute Inflammation)
5.1.2.2. Moderate Stage (Acute Inflammation with Leaky Fluid)
5.1.2.3. Severe Stage (Chronic Ulcer with Cell Necrosis)
5.1.2.4. Very Severe Stage (Chronic Open Wound)
5.1.2.5. Last Stage (Amputation)
5.2. Treatment Line of PRP Therapy Vs. Indication (Specific stages /occasions used in each indication)
5.3. Product USPs/ Features
5.4. Product Adoption / Usage Analysis
5.5. Regulatory Scenario
5.6. Surgical Procedure Volume Analysis for Top Countries
6. Global Autologous Conditioned Plasma Therapy Market Volume (Units) Analysis 2015-2019 and Forecast, 2020-2030
6.1. Historical Market Volume (Units) Analysis, 2015-2019
6.2. Current and Future Market Volume (Units) Projections, 2020-2030
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Autologous Conditioned Plasma Therapy Market – Pricing Analysis
7.1. Regional Pricing Analysis By Composition Type
7.2. Pricing Break-up
7.2.1. Manufacturer Level Pricing
7.2.2. Distributor Level Pricing
7.3. Global Average Pricing Analysis Benchmark
8. Global Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030
8.1. Historical Market Value (US$ Mn) Analysis, 2015-2019
8.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Opportunity Analysis, 2020-2030
9. Global Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030, By Composition Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Composition Type, 2015–2019
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Composition Type, 2020-2030
9.3.1. Pure Platelet-Rich Plasma (P-PRP)
9.3.2. Leukocyte- and Platelet-Rich Plasma (LPRP)
9.3.3. Pure Platelet-Rich Fibrin (P-PRF)
9.3.4. Leukocyte- and Platelet-Rich Fibrin (L-PRF)
9.4. Market Attractiveness Analysis By Composition Type
10. Global Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030, By Source
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Source, 2015–2019
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Source, 2020-2030
10.3.1. Autologous Platelet-Rich Plasma
10.3.2. Allogenic Platelet-Rich Plasma
10.3.3. Homologues Platelet-Rich Plasma
10.4. Market Attractiveness Analysis By Source
11. Global Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030, By Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015–2019
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2020-2030
11.3.1. Skin Ulcers
11.3.1.1. Venous Ulcers
11.3.1.2. Arterial Ulcers
11.3.1.3. Diabetic Foot Ulcers
11.3.2. Bone Fractures and Grafts
11.3.3. Prostheses Surgeries
11.3.4. Oral Implantology
11.3.5. Sport Injuries & Trauma
11.3.6. Cosmetic Surgery
11.3.7. Others
11.4. Market Attractiveness Analysis By Indication
12. Global Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030, By End User
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By End User, 2015–2019
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2020-2030
12.3.1. Hospitals
12.3.2. Specialized Clinics
12.3.3. Ambulatory Surgical Centers
12.3.4. Orthopedic & Trauma Centers
12.3.5. Research Institutes
12.4. Market Attractiveness Analysis By End User
13. Global Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030, by Region
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis By Region, 2015–2019
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2030
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia & Oceania
13.3.6. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region
14. North America Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
14.3.1. By Country
14.3.1.1. U.S.
14.3.1.2. Canada
14.3.2. By Composition Type
14.3.3. By Source
14.3.4. By Indication
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.5. Key Market Participants – Intensity Mapping
14.6. Drivers and Restraints – Impact Analysis
15. Latin America Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
15.3.1. By Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Composition Type
15.3.3. By Source
15.3.4. By Indication
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.5. Key Market Participants – Intensity Mapping
15.6. Drivers and Restraints – Impact Analysis
16. Europe Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. U.K.
16.3.1.5. Spain
16.3.1.6. Russia
16.3.1.7. Rest of Europe
16.3.2. By Composition Type
16.3.3. By Source
16.3.4. By Indication
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.5. Key Market Participants – Intensity Mapping
16.6. Drivers and Restraints – Impact Analysis
17. South Asia and Oceania Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
17.3.1. By Country
17.3.1.1. India
17.3.1.2. ASEAN
17.3.1.3. Australia
17.3.1.4. New Zealand
17.3.2. By Composition Type
17.3.3. By Source
17.3.4. By Indication
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.5. Key Market Participants – Intensity Mapping
17.6. Drivers and Restraints – Impact Analysis
18. East Asia Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Composition Type
18.3.3. By Source
18.3.4. By Indication
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.5. Key Market Participants – Intensity Mapping
18.6. Drivers and Restraints – Impact Analysis
19. Middle East and Africa Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. South Africa
19.3.1.4. Rest of Middle East and Africa
19.3.2. By Composition Type
19.3.3. By Source
19.3.4. By Indication
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.5. Key Market Participants – Intensity Mapping
19.6. Drivers and Restraints – Impact Analysis
20. Key and Emerging Countries Autologous Conditioned Plasma Therapy Market Analysis 2015-2019 and Forecast 2020-2030
20.1. Introduction
20.1.1. Market Value Proportion Analysis, By Key Countries
20.1.2. Global Vs. Country Growth Comparison
20.2. China Autologous Conditioned Plasma Therapy Market Analysis
20.2.1. By Composition Type
20.2.2. By Source
20.2.3. By Indication
20.2.4. By End User
20.3. Brazil Autologous Conditioned Plasma Therapy Market Analysis
20.3.1. By Composition Type
20.3.2. By Source
20.3.3. By Indication
20.3.4. By End User
20.4. India Autologous Conditioned Plasma Therapy Market Analysis
20.4.1. By Composition Type
20.4.2. By Source
20.4.3. By Indication
20.4.4. By End User
20.4.5.
20.5. U.S. Autologous Conditioned Plasma Therapy Market Analysis
20.5.1. By Composition Type
20.5.2. By Source
20.5.3. By Indication
20.5.4. By End User
20.6. Canada Autologous Conditioned Plasma Therapy Market Analysis
20.6.1. By Composition Type
20.6.2. By Source
20.6.3. By Indication
20.6.4. By End User
20.7. Mexico Autologous Conditioned Plasma Therapy Market Analysis
20.7.1. By Composition Type
20.7.2. By Source
20.7.3. By Indication
20.7.4. By End User
20.8. U.K. Autologous Conditioned Plasma Therapy Market Analysis
20.8.1. By Composition Type
20.8.2. By Source
20.8.3. By Indication
20.8.4. By End User
20.9. Germany Autologous Conditioned Plasma Therapy Market Analysis
20.9.1. By Composition Type
20.9.2. By Source
20.9.3. By Indication
20.9.4. By End User
20.10. France Autologous Conditioned Plasma Therapy Market Analysis
20.10.1. By Composition Type
20.10.2. By Source
20.10.3. By Indication
20.10.4. By End User
20.11. Italy Autologous Conditioned Plasma Therapy Market Analysis
20.11.1. By Composition Type
20.11.2. By Source
20.11.3. By Indication
20.11.4. By End User
20.12. Spain Autologous Conditioned Plasma Therapy Market Analysis
20.12.1. By Composition Type
20.12.2. By Source
20.12.3. By Indication
20.12.4. By End User
20.13. BENELUX Autologous Conditioned Plasma Therapy Market Analysis
20.13.1. By Composition Type
20.13.2. By Source
20.13.3. By Indication
20.13.4. By End User
20.14. Russia Autologous Conditioned Plasma Therapy Market Analysis
20.14.1. By Composition Type
20.14.2. By Source
20.14.3. By Indication
20.14.4. By End User
20.15. Japan Autologous Conditioned Plasma Therapy Market Analysis
20.15.1. By Composition Type
20.15.2. By Source
20.15.3. By Indication
20.15.4. By End User
20.16. South Korea Autologous Conditioned Plasma Therapy Market Analysis
20.16.1. By Composition Type
20.16.2. By Source
20.16.3. By Indication
20.16.4. By End User
20.17. ASEAN Autologous Conditioned Plasma Therapy Market Analysis
20.17.1. By Composition Type
20.17.2. By Source
20.17.3. By Indication
20.17.4. By End User
20.18. Australia Autologous Conditioned Plasma Therapy Market Analysis
20.18.1. By Composition Type
20.18.2. By Source
20.18.3. By Indication
20.18.4. By End User
20.19. New Zealand Autologous Conditioned Plasma Therapy Market Analysis
20.19.1. By Composition Type
20.19.2. By Source
20.19.3. By Indication
20.19.4. By End User
20.20. GCC Countries Autologous Conditioned Plasma Therapy Market Analysis
20.20.1. By Composition Type
20.20.2. By Source
20.20.3. By Indication
20.20.4. By End User
20.21. Turkey Autologous Conditioned Plasma Therapy Market Analysis
20.21.1. By Composition Type
20.21.2. By Source
20.21.3. By Indication
20.21.4. By End User
20.22. South Africa Autologous Conditioned Plasma Therapy Market Analysis
20.22.1. By Composition Type
20.22.2. By Source
20.22.3. By Indication
20.22.4. By End User
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies
21.2. Market Share Analysis of Top Players
21.3. Market Presence Analysis
21.3.1. Regional Footprint by Players
21.3.2. Product Foot print by Players
21.3.3. Channel Foot Print by Players
22. Competition Analysis
22.1. Competition Dashboard
22.2. Competition Benchmarking
22.3. Competition Deep Dive (Tentative List)
22.3.1. Zimmer Biomet Inc.
22.3.1.1. Overview
22.3.1.2. Product Portfolio
22.3.1.3. Profitability by Market Segments (Product/Channel/Region)
22.3.1.4. Sales Footprint
22.3.1.5. Strategy Overview
22.3.1.6. Marketing Strategy
22.3.1.7. Product Strategy
22.3.1.8. Channel Strategy
22.3.2. Terumo Corporation
22.3.2.1. Overview
22.3.2.2. Product Portfolio
22.3.2.3. Profitability by Market Segments (Product/Channel/Region)
22.3.2.4. Sales Footprint
22.3.2.5. Strategy Overview
22.3.2.6. Marketing Strategy
22.3.2.7. Product Strategy
22.3.2.8. Channel Strategy
22.3.3. DePuy Synthes, Inc. (DePuy Mitek Sports Medicine)
22.3.3.1. Overview
22.3.3.2. Product Portfolio
22.3.3.3. Profitability by Market Segments (Product/Channel/Region)
22.3.3.4. Sales Footprint
22.3.3.5. Strategy Overview
22.3.3.6. Marketing Strategy
22.3.3.7. Product Strategy
22.3.3.8. Channel Strategy
22.3.4. AdiStem Ltd.
22.3.4.1. Overview
22.3.4.2. Product Portfolio
22.3.4.3. Profitability by Market Segments (Product/Channel/Region)
22.3.4.4. Sales Footprint
22.3.4.5. Strategy Overview
22.3.4.6. Marketing Strategy
22.3.4.7. Product Strategy
22.3.4.8. Channel Strategy
22.3.5. Arthrex, Inc.
22.3.5.1. Overview
22.3.5.2. Product Portfolio
22.3.5.3. Profitability by Market Segments (Product/Channel/Region)
22.3.5.4. Sales Footprint
22.3.5.5. Strategy Overview
22.3.5.6. Marketing Strategy
22.3.5.7. Product Strategy
22.3.5.8. Channel Strategy
22.3.6. Stryker Corporation
22.3.6.1. Overview
22.3.6.2. Product Portfolio
22.3.6.3. Profitability by Market Segments (Product/Channel/Region)
22.3.6.4. Sales Footprint
22.3.6.5. Strategy Overview
22.3.6.6. Marketing Strategy
22.3.6.7. Product Strategy
22.3.6.8. Channel Strategy
22.3.7. Cesca Therapeutics, Inc.
22.3.7.1. Overview
22.3.7.2. Product Portfolio
22.3.7.3. Profitability by Market Segments (Product/Channel/Region)
22.3.7.4. Sales Footprint
22.3.7.5. Strategy Overview
22.3.7.6. Marketing Strategy
22.3.7.7. Product Strategy
22.3.7.8. Channel Strategy
22.3.8. Biotechnology Institute BTI
22.3.8.1. Overview
22.3.8.2. Product Portfolio
22.3.8.3. Profitability by Market Segments (Product/Channel/Region)
22.3.8.4. Sales Footprint
22.3.8.5. Strategy Overview
22.3.8.6. Marketing Strategy
22.3.8.7. Product Strategy
22.3.8.8. Channel Strategy
22.3.9. Dr. PRP America LLC
22.3.9.1. Overview
22.3.9.2. Product Portfolio
22.3.9.3. Profitability by Market Segments (Product/Channel/Region)
22.3.9.4. Sales Footprint
22.3.9.5. Strategy Overview
22.3.9.6. Marketing Strategy
22.3.9.7. Product Strategy
22.3.9.8. Channel Strategy
22.3.10. EmCyte Corporation
22.3.10.1. Overview
22.3.10.2. Product Portfolio
22.3.10.3. Profitability by Market Segments (Product/Channel/Region)
22.3.10.4. Sales Footprint
22.3.10.5. Strategy Overview
22.3.10.6. Marketing Strategy
22.3.10.7. Product Strategy
22.3.10.8. Channel Strategy
22.3.11. Vivostat A/S
22.3.11.1. Overview
22.3.11.2. Product Portfolio
22.3.11.3. Profitability by Market Segments (Product/Channel/Region)
22.3.11.4. Sales Footprint
22.3.11.5. Strategy Overview
22.3.11.6. Marketing Strategy
22.3.11.7. Product Strategy
22.3.11.8. Channel Strategy
22.3.12. Regen Lab SA
22.3.12.1. Overview
22.3.12.2. Product Portfolio
22.3.12.3. Profitability by Market Segments (Product/Channel/Region)
22.3.12.4. Sales Footprint
22.3.12.5. Strategy Overview
22.3.12.6. Marketing Strategy
22.3.12.7. Product Strategy
22.3.12.8. Channel Strategy
22.3.13. Royal Biologics
22.3.13.1. Overview
22.3.13.2. Product Portfolio
22.3.13.3. Profitability by Market Segments (Product/Channel/Region)
22.3.13.4. Sales Footprint
22.3.13.5. Strategy Overview
22.3.13.6. Marketing Strategy
22.3.13.7. Product Strategy
22.3.13.8. Channel Strategy
22.3.14. Exactech, Inc.
22.3.14.1. Overview
22.3.14.2. Product Portfolio
22.3.14.3. Profitability by Market Segments (Product/Channel/Region)
22.3.14.4. Sales Footprint
22.3.14.5. Strategy Overview
22.3.14.6. Marketing Strategy
22.3.14.7. Product Strategy
22.3.14.8. Channel Strategy
22.3.15. Plateltex S.R.O.
22.3.15.1. Overview
22.3.15.2. Product Portfolio
22.3.15.3. Profitability by Market Segments (Product/Channel/Region)
22.3.15.4. Sales Footprint
22.3.15.5. Strategy Overview
22.3.15.6. Marketing Strategy
22.3.15.7. Product Strategy
22.3.15.8. Channel Strategy
23. Assumptions and Acronyms Used
24. Research Methodology
Table 01: Global Autologous Conditioned Plasma Therapy Market Volume (‘000 Units) Analysis and Opportunity Assessment 2015–2030, By Composition TypeTable 02: Global Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment
2015–2030, By Composition Type
Table 03: Global Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment
2015–2030, By Source
Table 04: Global Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment
2015–2030, By Indication
Table 05: Global Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment
2015–2030, By End User
Table 06: Global Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment
2015–2030, By Region
Table 07: North America Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Country
Table 08: North America Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Composition Type
Table 09: North America Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Source
Table 10: North America Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication
Table 11: North America Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By End User
Table 12: Latin America Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Country
Table 13: Latin America Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Composition Type
Table 14: Latin America Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Source
Table 15: Latin America Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication
Table 16: Latin America Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By End User
Table 17: Europe Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Country
Table 18: Europe Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Composition Type
Table 19: Europe Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Source
Table 20: Europe Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication
Table 21: Europe Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By End User
Table 22: South Asia Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Country
Table 23: South Asia Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Composition Type
Table 24: South Asia Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Source
Table 25: South Asia Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication
Table 26: South Asia Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By End User
Table 27: East Asia Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Country
Table 28: East Asia Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Composition Type
Table 29: East Asia Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Source
Table 30: East Asia Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication
Table 31: East Asia Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By End User
Table 32: Oceania Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Country
Table 33: Oceania Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Composition Type
Table 34: Oceania Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Source
Table 35: Oceania Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication
Table 36: Oceania Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By End User
Table 37: Middle East and Africa Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Country
Table 38: Middle East and Africa Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and
Opportunity Assessment 2015–2030, By Composition Type
Table 39: Middle East and Africa Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and
Opportunity Assessment 2015–2030, By Source
Table 40: Middle East and Africa Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and
Opportunity Assessment 2015–2030, By Indication
Table 41: Middle East and Africa Autologous Conditioned Plasma Therapy Market Value (US$ Mn) Analysis and
Opportunity Assessment 2015–2030, By End User